Welcome

We are delighted to present the Summer 2018 issue of the PeDRA Post. This publication brings to light the research initiatives and direction of growth for our dynamic organization.

PeDRA members collaborate to advance research and optimize the care of children with a variety of dermatology diseases and conditions. There are more than 40 interesting and vital projects now under the PeDRA banner. Take a look in this issue at the newly-launched cross-PeDRA study on burden of disease for children with skin diseases. Also, we summarize PeDRA’s visit to the NIH and FDA in May.

The stories and updates in this newsletter remind me how important it is that we all stay focused on research. Scientific investigations, and the answers they yield, lead to hope and a brighter future in pediatric dermatology.

Elena
Elena Pope, Chair, PeDRA Communications Committee
Milestone Clinical Events in Patients with EB (Anna Bruckner, MD, EB Medical Research Foundation) 4

Characterization of Wound Colonizers and Skin Care Practices (Anna Bruckner, MD, EB Medical Research Foundation) 6

SUMMER 2018

TABLE OF CONTENTS

Click on a topic to jump to the content that you want to read. Use the << BACK button to return to this page.

Updates from PeDRA Study Groups 3

PeDRA's first cross-disease study has launched! 7
Early career investigators hard at work in PeDRA 7 – 8
Patient advocacy news board 8 – 10
PeDRA brings pediatric dermatology message to NIH and the FDA 10
Show me the money—PeDRA grants 10
Research tools and resources 10 – 11
PeDRA membership 11
Important dates and reminders 12

PeDRA POST SUMMER 2018

SUMMER 2018

UPDATES FROM PeDRA STUDY GROUPS

Collaborative groups of investigators are working under the PeDRA umbrella to advance pediatric dermatology studies.

Birthmarks and Procedural

The Birthmarks group has continued to study both vascular birthmarks as well as pigmented lesions. We are proud of the three PeDRA Birthmark studies that were accepted for presentation at the International Society for the Study of Vascular Anomalies (ISSVA) meeting in Amsterdam in May 2018. Investigators from our group presented the findings of the survey study looking at current management of infantile hemangiomata, the large multi-center retrospective study on the evaluation of PHACE syndrome and the retrospective cohort study regarding the use of topical sirolimus in the setting of superficial lymphatic malformations. Other ongoing studies including the multicenter genotype-phenotype study of children with vascular overgrowth syndromes, genetic mosaicism in PHACE syndrome, a study examining the effect of vascular anomalies on patient quality-of-life, and a study looking at ulcerated hemangiomata continue to make great progress. We are excited about studies in the pipeline including a retrospective cohort study on genital infantile hemangiomata, and several ideas in conjunction with the Sturge Weber Foundation. The pigmented lesion subgroup is also planning to initiate exciting studies to develop consensus guidelines for management of congenital melanocytic nevi, examine the role of MRI to detect neurocutaneous melanosis, and pursue mapping primary congenital melanocytic nevi and their satellite lesions.

For more information, please contact: Joyce Tang, MD, PhD (jtang3@stanford.edu) or Harper Price, MD, PhD (hprice@phoenixchildrens.com)

Disorders of Cornification (DOC) Subgroup

The DOC working group, PeDRA, and other collaborators have enrolled 1000 subjects in the National Registry for Ichthyosis and Related Skin Types. This project seeks to identify novel genetic causes of ichthyosis and to understand disease pathobiology. The study continues to enroll subjects with disorders of keratinization/cornification, collecting clinical information, photographs, and a saliva or blood sample for genetic analysis. Enrolled subjects will have the opportunity to participate in clinical trials and studies of disease nature history.

For more information, please contact: Keith Choate, MD, PhD (keith.choate@yale.edu)

Epidermolysis Bullosa Subgroup

The Epidermolysis Bullosa Clinical Research Consortium (EBCRC) currently has 20 centers in the US and Canada. EBCRC’s main project, the EB Clinical Characterization and Outcomes Database (EBCCOD) is continuing to enroll new subjects. There are over 700 patients enrolled in this study, which is supported by EB Research Partnership and EB Medical Research Foundation. Two studies using data collected for the EBCCOD are underway:

- Milestone Clinical Events in Patients with EB (Anna Bruckner, PI) describes the range of EB patients presenting to EBCRC providers that provides data about key clinical events in the diagnosis, course, and management of EB, termed milestone events. Grant funding from Amicus Therapeutics has been awarded for this study.

- Characterization of Wound Colonizers and Skin Care Practices in EB (Laura Levin and Kim Morel, PI) is a two-part study that summarizes results of hundreds of wound cultures in patients improved interventions, and better outcomes. There has been exciting development of therapeutics for basal cell carcinoma and BCCNS in adults. The safety of such new therapy options can only be evaluated in pediatric patients through collaborative research.

For more information, please contact: Laura Levin, MD, (llevin@med.unc.edu) or Krista Morel, MD (kmorel@stanford.edu)

Genetic Skin Disorders

Basal Cell Carcinoma Nevus Syndrome and Other Genodermatoses

Most patients with basal cell carcinoma nevus syndrome (BCCNS) are diagnosed between 17 and 35 years of age. Our research goal is to establish a centralized clinical database to enroll pediatric patients during early childhood. The registry will collect information including genotyping, disease progression, surveillance, and interventions. Our objective is to improve the understanding of genotype-phenotype correlation of the disease as well as its manifestation and responses to interventions. We hope this coordinated effort will advance our knowledge about BCCNS that will lead to early diagnosis, improved interventions, and better outcomes. There has been exciting development of therapeutics for basal cell carcinoma and BCCNS in adults. The safety of such new therapy options can only be evaluated in pediatric patients through collaborative research.

For more information, please contact: Laura Levin, MD, (llevin@med.unc.edu) or Krista Morel, MD (kmorel@stanford.edu)

Research tools and resources 10 – 11
PeDRA membership 11
Important dates and reminders 12

For more information, please contact: Keith Choate, MD, PhD (keith.choate@yale.edu)
from EB and will also report patient-reported skin care practices. EB Research Partnership has provided additional support for this study.

Studies in the earlier stages include: 

- a comparison of diagnostic tests used in EB, transition to adult care, and anemia. EBRC members are also actively involved in collaborative studies about Esophageal strictures (Elena Pope, PI) and developing clinical practice guidelines for anemia (led by Irene Lara-Corrales and Carmen Lee in conjunction with DEBRA International).

For more information, please contact: 
Anna Bruckner, MD (anna.bruckner@ucdenver.edu) 

**Inflammatory Skin Disorders**

### Acne and Hidradenitis Subgroup

Epidemiologic data of hidradenitis suppurativa (HS) in children is lacking. We are completing this retrospective characterization of pediatric patients with hidradenitis suppurativa to better understand this disorder. By reviewing the clinical presentation and management of HS in children, our goal is to create an efficient protocol for treating this condition and preventing its complications. We have recruited 8 sites for this study, most sites already have IRB approval and are collecting data. We have already completed data collection in 6 sites and will receive data from the remaining 2 sites by the end of June. We received an Abbvie Grant for the completion of this study.

For more information, please contact: 
Irene Lara-Corrales (irene.lara-corrales@slckids.ca)

### Atopic Dermatitis Subgroup

“Atopic Dermatitis: An Assessment of Lesional Morphology by Race/Ethnicity” was recently awarded a PsDRA Team Grant—this prospective study will systematically evaluate the major morphologic subtypes of disease in U.S. and Canadian children with AD. Untrained or minimally treated AD and severe, recalcitrant AD disease impact will be assessed over 2 visits. IRB and data collection templates are near finalized.

A second initiative, being led by Elaine Siegfried, pools the cumulative experience with off-label use of dupilumab in children. The hope is to increase access by providing more response and side effect data.

Our understanding of AD pathogenesis and the number of emerging therapies are increasing. At a rapid pace—other project ideas are welcome!

For more information or to participate, please contact: 
Molly Lu (mlu@chla.usc.edu)

For more information or to contribute additional pediatric cases, please contact: 
Eaine Siegfried (elaine.siegfried@health.iu.edu)

For more information, or if you have project ideas, please contact: 
Wynnis Tom (wtom@rchsd.org) or Larry Eichenfield (leichenfield@rchsd.org)

### Connective Tissue Disease Subgroup

The Connective Tissue Disease subgroup continues to thrive with several active studies.

- CARRA collaborations have continued and PsDRA members again attended the CARRA meeting this year. PsDRA and CARRA are working together on a retrospective study of discoid lupus erythematosus, funded by a CARRA grant, which will pave the way for a prospective study looking at progression to systemic lupus erythematosus.

- We are working with CARRA on a survey assessing sun protection counseling by pediatric rheumatologists and sun protection practices by pediatric rheumatology patients.

- A study was conducted at the University of Pennsylvania, in collaboration with Dr. Victoria Werth and CARRA, to validate the Cutaneous Lupus Activity and Severity Index (CLASI).

- Initial plans are underway to undertake a retrospective study of amyopathic dermatomyositis.

- The morphea registry continues to enroll patients, and genetic studies are ongoing. Data analysis is progressing for the morphea mapping study funded by a PsDRA pilot grant in 2015, and preliminary results were presented at the 2017 PsDRA Annual Conference and the 2018 International Investigative Dermatology Meeting.

- We are continuing our work to develop an outcome measure for morphea, while also working on a scoring system for the diagnosis and evaluation of genital lichen sclerosus.

The Connective Tissue Disease subgroup welcomes new members and is recruiting additional investigators for its studies; trainees and early investigators are encouraged to participate.

For more information, please contact: 
Yvonne Chiu (ychiu@mcw.edu)

### Genetic Investigation of Cutaneous Mosaic Disorders

Cutaneous mosaic disorders appear in patterns due to a somatic mutation during embryonic development. We have successfully identified several novel genetic causes of these conditions and now seek to enroll new subjects with cutaneous mosaic disorders. We screen for mutations in potential causative genes, and employ exome or genome sequencing in mutation-unknown subject to discover novel genetic causes. We seek proliferative/hamartomatous conditions including congenital focal dysplasty, nevus comedonicus, and congenital hemangiomas, as well as rare mosaic presentations of common disorders including acne, psoriasis, lichen planus, and discoid lupus erythematosus.

For more information, please contact: 
Keith Choate MD, PhD (keith.choate@yale.edu)

### Hair/Nail/Other Autoimmune Subgroup

Quality of life of caregivers is critical to family centered medicine. This study aims to evaluate quality of life (QoL) in caregivers of children with alopecia areata, tattals and unibrow. Using two previously validated QoL scales for caregivers as well as severity of alopecia tool (SALT) scores, we aim to measure caregivers’ QoL, impairment and determine its relationship to severity of disease. This may be helpful in tailoring education and tools for families. Approximately 150 participants have been enrolled, and data collection among the 4 participating institutions will be completed by July 1, 2018.

For more information or to collaborate, please contact: 
Elena Puttermann (puttermane@email.chop.edu) or Leslie Castello-Soccor (castellosocioc@email.chop.edu)

### Psoriasis Investigator Group (PsIG):

- The CAPP Survey (Clinical Approaches to Pediatric Psoriasis) in the US and Canada led by Kelly Cordoro at UCSF is in the final stages of re-analysis and manuscript preparation. Look for a publication in 2018.


- PsIG members and other multidisciplinary experts developed the first set of pediatric psoriasis comorbidity screening guidelines led by Drs. Duier, Wang and Eichenfield and has been published in JAMA Dermatology: JAMA Dermatol. 2017 Jul 1;153(7):698-704. We have developed an online app to facilitate the screening process, which will be available shortly. We are open to new sites joining our study to formally assess pre- and post-app ease of screening. Please contact Wynnis Tom, MD (wtom@rchsd.org) for more information.

- A series on patients with TINF-induced psoriasis dermatitis led by Megha Tollefson at Mayo is in the data analysis phase and is closed for enrollment.

- A Delphi methodology/study to determine best laboratory screening practices for systemic and biologic therapies is in the planning phases and will be jointly led by UCSF and Northwestern.

If you are interested in joining this group, have study ideas or would like to participate in other PsIG studies, please contact: 
Co-Chair, Kelly Cordoro, MD (kelly.cordoro@uscsf.edu) or Co-Chair Amy Paller, MD (apaller@northwestern.edu)

**PsDRA POST SUMMER 2018**

<< BACK
The neonatal skin working group has developed a survey to collect large scale data across North America regarding hospital-based skin care practices in premature and full-term neonates. This project is pursuing funding opportunities to implement. Data from this study will offer insights into variations in current practice and will help inform the development of consensus neonatal skin care guidelines.

A pilot study examining clinical outcomes of atelibrneonates with pustulosis was completed, and results have been accepted for publication. This project will be expanded to other institutions to collect more robust data with a goal of developing a clinical practice algorithm.

A multi-institutional project which aims to characterize cutaneous graft versus host disease among dermatologists and transplant providers.

For more information, please contact:
Elaine Siegfried (elaine.siegfried@health.slu.edu) or Heather Brandling-Bennett (Heather.Brandling-Bennett@seattlechildrens.org)

PeDRA'S FIRST CROSS-DISEASE STUDY HAS LAUNCHED!

PeDRA’s Stigma, Anxiety and Depression in Children and Adolescents with Skin Disorders—the “Big Study” will assess anxiety, depression, and social functional issues in addition to stigma in children with skin diseases. Thanks to a sizable grant from Regeneron, combined with PeDRA’s own investment and support from patient advocacy organizations, the project has launched!

Amy Paller, PI, is deeply invested in measuring the psychosocial impact of skin diseases in children. This novel study leverages a new instrument to measure pediatric stigma, and combines it with scales to measure social functioning, anxiety and depression in children. The study compares how a child and his/her parent view these impacts differently. By engaging so many pediatric dermatology researchers via the PeDRA network, participation and input from thousands of children with potentially stigmatizing skin problems is anticipated.

THE GOAL:
To educate the public, patients, industry, and physicians about the magnitude of the burden of highly visible skin disorders—and ultimately to introduce new therapies that can measurably alleviate this childhood burden.

The PeDRA Stigma Project Currently Has:

- 39 Interested Sites
- 71 Investigators
- Tentative Timeline: July/August 2018

Stephanie Rangel is the manager of the study. For more information, please contact stephanie.rangel@nm.org.

Please invite families... who want to support research to back this project! For information on how to support the Stigma study, please contact Sheila Rittenberg, sheila.pedraresearch@gmail.com. For information on participating in the study, contact Amy Paller, MD, (apaller@nm.org). Sarah Chamlin (schamlin@luriechildrens.org) or Stephanie Rangel (stephanie.rangel@nm.org).

A HEARTY NOTE OF THANKS...

ALL of you in the PeDRA community have contributed your time and talents and have helped further the common goal of helping children in their field. We vowed to help. My goal was to create lasting relationships and helping to bridge the worlds of industry and academic medicine. Dana tells us that in her early career, “…Without early guidance, I could not have achieved my research success. At my first PeDRA Hour with Dana Hardin I learned that younger pediatric dermatologists were much like I was when I joined academic faculty. They were hungry to learn and represented the future of helping children in their field. I vowed to help. My goal was to create lasting learning for young faculty.”

The PeDRA Investigators Committee (EIC) welcomed 4 new members to our committee this spring—Elena Hawryluk (MGH/Harvard), Dominique Pichard (NH), Deepti Gupta (Seattle Children’s/University of Washington), and Amy Mathur (LJCF). Our committee remains dedicated to increasing the breadth and depth of programming and resources specifically for early investigators (~7 years out of training). To that end, our next webinar, an outgrowth of a partnership with Eli Lilly will explore the relationship between industry and academic medicine.

The Early Investigators Committee (EIC) welcomed 4 new members to our committee this spring—Elena Hawryluk (MGH/Harvard), Dominique Pichard (NH), Deepti Gupta (Seattle Children’s/University of Washington), and Amy Mathur (LJCF). Our committee remains dedicated to increasing the breadth and depth of programming and resources specifically for early investigators (~7 years out of training). To that end, our next webinar, an outgrowth of a partnership with Eli Lilly will explore the relationship between industry and academic medicine.

Aligning Academia & Industry Research Interests—The Path to Solutions for Our Patients is a “deep dive” into the relationship between industry and academia. Geared for junior faculty interested in clinical trials who may have limited industry experience, the webinar features Dr. Adelaide Hebert and Dr. Kenneth Gordon, two senior academicians, discussing the role of academics in industry, ethical issues surrounding clinical trials, and pearls/pitfalls for succeeding as a principal investigator. Watch https://pedraresearch.org/resources-for-researchers for more information.

The Early Investigators Committee (EIC) welcomed 4 new members to our committee this spring—Elena Hawryluk (MGH/Harvard), Dominique Pichard (NH), Deepti Gupta (Seattle Children’s/University of Washington), and Amy Mathur (LJCF). Our committee remains dedicated to increasing the breadth and depth of programming and resources specifically for early investigators (~7 years out of training). To that end, our next webinar, an outgrowth of a partnership with Eli Lilly will explore the relationship between industry and academic medicine.

Aligning Academia & Industry Research Interests—The Path to Solutions for Our Patients is a “deep dive” into the relationship between industry and academia. Geared for junior faculty interested in clinical trials who may have limited industry experience, the webinar features Dr. Adelaide Hebert and Dr. Kenneth Gordon, two senior academicians, discussing the role of academics in industry, ethical issues surrounding clinical trials, and pearls/pitfalls for succeeding as a principal investigator. Watch https://pedraresearch.org/resources-for-researchers for more information.

The Early Investigators Committee (EIC) welcomed 4 new members to our committee this spring—Elena Hawryluk (MGH/Harvard), Dominique Pichard (NH), Deepti Gupta (Seattle Children’s/University of Washington), and Amy Mathur (LJCF). Our committee remains dedicated to increasing the breadth and depth of programming and resources specifically for early investigators (~7 years out of training). To that end, our next webinar, an outgrowth of a partnership with Eli Lilly will explore the relationship between industry and academic medicine.

Aligning Academia & Industry Research Interests—The Path to Solutions for Our Patients is a “deep dive” into the relationship between industry and academia. Geared for junior faculty interested in clinical trials who may have limited industry experience, the webinar features Dr. Adelaide Hebert and Dr. Kenneth Gordon, two senior academicians, discussing the role of academics in industry, ethical issues surrounding clinical trials, and pearls/pitfalls for succeeding as a principal investigator. Watch https://pedraresearch.org/resources-for-researchers for more information.

The Early Investigators Committee (EIC) welcomed 4 new members to our committee this spring—Elena Hawryluk (MGH/Harvard), Dominique Pichard (NH), Deepti Gupta (Seattle Children’s/University of Washington), and Amy Mathur (LJCF). Our committee remains dedicated to increasing the breadth and depth of programming and resources specifically for early investigators (~7 years out of training). To that end, our next webinar, an outgrowth of a partnership with Eli Lilly will explore the relationship between industry and academic medicine.

Aligning Academia & Industry Research Interests—The Path to Solutions for Our Patients is a “deep dive” into the relationship between industry and academia. Geared for junior faculty interested in clinical trials who may have limited industry experience, the webinar features Dr. Adelaide Hebert and Dr. Kenneth Gordon, two senior academicians, discussing the role of academics in industry, ethical issues surrounding clinical trials, and pearls/pitfalls for succeeding as a principal investigator. Watch https://pedraresearch.org/resources-for-researchers for more information.
EARLY CAREER INVESTIGATORS HARD AT WORK IN PeDRA

Early career investigator briefs

Annual Conference
This year’s PeDRA Annual Conference will feature another dedicated Early Investigator’s Forum (EI Forum) on Thursday, October 25th. The theme this year is “Cultivating Collaboration through Communication.” This engaging session focuses on improving skills to maximize your work productivity. Stay tuned for a confirmed line up of speakers! Are there topics that you would like to see covered in a future PeDRA EI Forum? Please send ideas to Lisa Arkin (larkin@dermatology.wisc.edu). We would love to hear from you!

Mentorship program
The mentorship program is off to another great year. We received helpful constructive feedback last year and are building infrastructure to further support the program, including quarterly emails with grant deadlines, resources for maximizing your mentee-mentor relationship, and new articles that catch our eye. Stay tuned for these in your inbox! If you have thoughts on this, please do not hesitate to contact Jenn Dawson (jenn.pedraresearch@gmail.com).

New EI webpage coming soon
And finally, we will soon be launching a dedicated webpage for early investigators! We think you’ll love our new webpage created just for you, our Early Investigators. This dedicated page will provide access to resources, critical updates, and essential information about early investigator-specific programming, such as the PeDRA Mentorship Program. Watch for the launch of this page in June 2018 at https://pedraresearch.org. Look for an “Early Investigators” tab.

BCCONS Alliance
The BCCNS Life Support Network recently changed its name to the BCCNS Alliance and announced a new logo and redesigned website. The updated look represents the organization’s new leadership and desire to build upon and strengthen their alliance between patients, medical professionals, the pharmacological industry, professional staff and lay leadership. The cell representation in the BCCNS Alliance’s new logo also signifies the organization’s increased emphasis on science and research towards improved treatments and a cure. The BCCNS Alliance continues to provide strong emotional and informational support for its members. The organization is hosting five regional, one-day meetings around the US this year and launching a peer-to-peer support network for patients to connect with others. A new patient registry will be launching in the late summer and promising drugs are in the pipeline for BCCNS along with an increasing focus by the pharmacological industry on this rare disease. For more information: https://bccns.org/bccns-alliance-home-new/home.

International Pemphigus & Pemphigoid Foundation (IPPF)
The International Pemphigus & Pemphigoid Foundation (IPPF) seeks to improve the quality of life for all people affected by pemphigus and pemphigoid through early diagnosis and support. The IPPF’s Annual Patient Conference focuses on connecting patients and their families to leading dermatologists and disease experts. This year’s event will be held in Durham, NC on October 12–14, 2018. The conference also shows patients that they are not alone in their experiences. To learn more about the Annual Patient Conference, as well as IPPF support groups, peer support, and other resources, visit www.pemphigus.org.

National Psoriasis Foundation
NPF encourages PeDRA members to get involved.

> Become a professional member for preferential listing in NPF’s provider directory, complimentary CME offerings, discounts on study recruitment, and more.

> Submit your research to the Journal of Psoriasis and Psoriatic Arthritis (www.psoriasis.org/jpaa)

> Become a site and enrol for the Corona Psoriasis Registry.

> And much more! Visit us online at www.pсорiasis.org.

Pachyonychia Congenita (PC) Project
Pachyonychia Congenita is an ultra-rare genetic autosomal dominant keratin disorder caused by a mutation in one of five keratin genes: KRT6A, KRT6B, KRT16, KRT17 or KRT17. PC is a chronically debilitating disease due to impaired ambulation associated with plantar keratoderma, blistering and pain that make walking difficult or impossible. Other common features of PC include palmar keratoderma, nail dystrophy, leukokeratosis in the mouth, cysts, follicular hyperkeratosis at the waist, knees, elbows and other high friction areas, all of which can be extremely painful for children.

PC Project’s annual Patient Support Meeting will be held in London, England October 19–21, 2018. Interested researchers and clinicians are invited to attend. For more information, please visit www.pachyonychia.org/news-events

Any PeDRA researcher interested in PC is invited to contact PC Project at info@pachyonychia.org and join the International Pachyonychia Congenita Consortium (IPCC), a network of physicians and scientists who collaborate in discovering new research and finding treatments for Pachyonychia Congenita and related skin disorders.

National Eczema Association
The National Eczema Association is pleased to announce our 2018 grant program. Grant applications will be requested in the following areas of investigation:

> Innovations in Basic Science Research

> Pediatric Eczema/Atopic Dermatitis: Novel Insights

> Innovations in Practice Care

> Patient/Caregiver Burden of Disease

Four NEA research grants will be awarded in the amount of $50,000 each. Submission deadlines and additional information available June 1st. For more information visit: https://nationaleczema.org/nea-funded-research.

National Psoriasis Foundation
NPF encourages PeDRA members to get involved.

> Become a professional member for preferential listing in NPF’s provider directory, complimentary CME offerings, discounts on study recruitment, and more.

> Submit your research to the Journal of Psoriasis and Psoriatic Arthritis (www.psoriasis.org/jpaa)

> Become a site and enrol for the Corona Psoriasis Registry.

> And much more! Visit us online at www.pсорiasis.org.

PhACE Syndrome Community
The PhACE Syndrome Community (PSC) will be holding its bi-annual family conference in Atlanta, June 29–July 1. Families will have access to the world’s leading PhACE physicians, conference materials and the ability to network with other PhACE families. The PSC asks that PeDRA members encourage their patients to attend. The NEW UPDATED Care Guidelines are now available to view through the PSC website www.phacesyndromecommunity.org. In addition, a Family Handbook is being updated and will provide a comprehensive educational resource for families who have a loved one affected with PhACE. The PSC is also excited to announce that the PhACE Syndrome International Clinical Registry and Genetic repository has been awarded a Gabriella Miller Kids First X01 grant.

Sturge-Weber Foundation
The Sturge-Weber Foundation will be hosting two Educational Conferences with Dr. Kristen Kelly at Beckman Laser Institute and with Dr. Harry Chugani at Nemours Hospital. For more information about these events please visit https://goo.gl/14wcpa

Neonatal Eczema (NJob)
The neonatal eczema framework is a long-term plan to identify and prioritize research gaps in neonatal eczema. The framework was developed by an integrated team of neonatal eczema (NEA) researchers and clinicians, parents and neonatal eczema advocacy groups.

Four NEA research grants will be awarded in the amount of $50,000 each. Submission deadlines and additional information available June 1st. For more information visit: https://nationaleczema.org/nea-funded-research.

National Psoriasis Foundation
NPF encourages PeDRA members to get involved.

> Become a professional member for preferential listing in NPF’s provider directory, complimentary CME offerings, discounts on study recruitment, and more.

> Submit your research to the Journal of Psoriasis and Psoriatic Arthritis (www.psoriasis.org/jpaa)

> Become a site and enrol for the Corona Psoriasis Registry.

> And much more! Visit us online at www.pсорiasis.org.
PeDRA brings Pediatric Dermatology Message to NIH and the FDA

Ilona Frieden adds, “… We left with optimism that these are only the first steps in collaboration with NIH scientists and in understanding how to strengthen NIH-PeDRA ties. Our meeting at the FDA was also a success. The FDA physicians were receptive and enthusiastic about PeDRA. We left feeling that a door had clearly been opened to find ways that the FDA may be able to assist us and in seeing PeDRA as a resource for the agency.”

JUST A SHORT WEEK FOLLOWING THE MEETING AT THE FDA, PeDRA WAS INVITED TO JOIN THE FDA NETWORK OF EXPERTS!

This is a vetted network of partner organizations and their member scientists, clinicians and engineers that provides expertise to supplement existing knowledge at the FDA. PeDRA is honored to be included and thrilled that pediatric dermatology is now represented in this important forum.

A THANK-YOU to Larry Eichenfield, Ilona Frieden, Amy Paller and Dawn Siegel for their expertise and for making the important trip to visit NIH and the FDA!

In 2016, PeDRA and the Society for Pediatric Dermatology (SPD) harmonized their grant programs by merging into one initiative. The joint program has been able to fund important and innovative multisite and single site applications. The next grant cycle is December 1, 2018. There is now an online portal for grant submissions, greatly streamlining the process. Announcements coming soon.

RESEARCH TOOLS & RESOURCES

*BASECAMP—Making Your Projects Easier.

Say goodbye to wasting time searching your files for the “that thing” you need. PeDRA members have access to Basecamp, project management software that can easily be downloaded to your computer or mobile device and allows you to effortlessly access, upload, edit and share files.

Some of Basecamp’s most appealing characteristics are that you are able to complete tasks any time you want. You can also have conversations with the whole study team or private conversations no one else can follow. Basecamp allows you to keep a project schedule, and stores files and documents in just one place, and keeps you connected to your teammates. Basecamp allows you to protect yourself—and your team members—from email fatigue. Basecamp will notify you each time there is activity in your project and you can decide what you hear about, and when you hear it.

Getting started is easy. Email Jenn Dawson, PeDRA Outreach Liaison at jenn.pedraresearch@gmail.com. She will set up your account and help you get the lay of the land. To learn more, please visit https://pedraresearch.org/resources-for-researchers.

We welcome feedback on Basecamp as a research tool for PeDRA use! Please contact Irene Lara-Corrales (irene.lara-corrales@sickkids.ca).

*CREATING A VOICE FOR PEDRA.

By entering and tracking all studies in our network we have the information we need to keep our network vibrant and healthy. This is essentially PeDRA’s voice and tracking studies provides the words, stories, and data to create that voice. Principal Investigators have been entering their studies, but we are still not complete. If you haven’t already updated your study, log in to your Account page and then scroll down to ‘PeDRA Study Updates.’ The entries from the last update will pop up, making it easy for you to update with only new information.

WHAT MAKES PEDRA RUN?

You hear from Sheila Rittenberg and Jenn Dawson but who else is making possible PeDRA’s work? We have a small, part-time team but it is one of the most efficient and dedicated to be found. One team member is Katherine who says, “I find great satisfaction working with PeDRA—it is exciting to work with so many investigators from different locations. I enjoy coordinating, our grants program, and in turn, watching important studies launch within our large network of collaborators.” Katherine Mueller Devenport, PeDRA’s part-time Outreach Liaison.

PeDRA Dues Online Please Visit: www.peds Derm.net/pedra. Active members pay $150 annually. Trainee members do not pay dues until their training period has ended.

NOT A PEDRA MEMBER? JOIN TODAY!

Our two-step application process is quick and simple. Apply for membership here: http://www.pedraresearch.org/membership-application.

TO APPLY FOR THE NEXT GRANT CYCLE:

Visit pedraresearch.org/grants-to-support-research.

TO VIEW CURRENT GRANT RECIPIENTS:

At the time of this writing, determinations are being made for the 2018 grants. Announcements coming soon.

*SEARCH FOR PROFESSIONALS.

How can you find collaborators for research projects? How can you better understand the strengths, interests and assets brought into the network by investigators? One easy answer: our “Search for Professionals” on pedraresearch.org (members only). In order for the Search to reflect the capacity of our members, it needs to be populated! If you haven’t already, please take a few moments to complete our research capacity survey: http://pedraresearch.org/research-capacity-survey. Your profile will then be integrated into the Search for Professionals.

TO PAY YOUR PeDRA DUES ONLINE PLEASE VISIT:

If you have questions about membership or your dues, please contact Jenn Dawson, Membership and Outreach Liaison at jenn.pedraresearch@gmail.com.

PeDRA MEMBERSHIP

Other specialists in our ranks

Recently, the PeDRA Membership Committee discussed a recruiting plan for new, non-pediatric dermatology members who can help round out PeDRA’s research efforts and strengthen our base. We need your help! We ask that you reach out to your colleagues conducting work in other relevant fields, tell them about PeDRA, and let them know their work is important to us and to pediatric dermatology. The committee has been reaching out to non-pediatric dermatologists in fields such as Infectious Diseases, Rheumatology, Allergy, Genetics, Hematology/Oncology, Neonatology, and Vascular Anomalies. Building these new relationships furthers PeDRA’s work and adds to our relevance. If colleagues in other fields are interested in learning more, please connect them with Jenn Dawson, PeDRA Membership and Outreach Liaison, jenn.pedraresearch@gmail.com.

PeDRA Membership Online Please Visit: www.pedsderm.net/pedra. Active members pay $150 annually. Trainee members do not pay dues until their training period has ended.

Please visit: https://pedraresearch.org/resources-for-researchers.
IMPORTANT DATES & REMINDERS

10/25 – 10/27/2018
SAVE THE DATE:
The 6th PeDRA Annual Conference, October 25-27, 2018
Hyatt Regency Aurora-Denver Conference Center, Aurora, CO
Watch for conference information here: https://pedraresearch.org/2018-conference

*NEW* THE RESEARCH HOT SEAT—A PeDRA SHARK TANK.
Awards funds for innovative research and takes place at the 2018 PeDRA Annual Conference.
To learn more and apply, watch for information here: https://pedraresearch.org/grants-to-support-research.

11/15/2018
DEADLINE TO SUBMIT SURVEY APPLICATION.
PeDRA reviews and approves surveys before dissemination to our members.

12/2018
DEADLINE FOR PeDRA GRANT SUBMISSIONS.
The next grant cycle deadline is in December 2018. Watch for details here: http://pedraresearch.org/grants-to-support-research.

THANK YOU
Thank you to the PeDRA Communications Committee for contributions to this newsletter!
Colleen Cotton  Cyndee DeKlotz  Elena Hawryluk  Kristen Hook  Raegan Hunt  Irene  Lara-Corrales  Marcia Hogeling  Christine Lauren
Marilyn Liang  Julianne Mann  Kalyani Marathe  Kimberly Morel  Elena Pope (Chair)  Kate Puttgen  Jillian Rork  Wynnis Tom

Helping Children with Skin Diseases through Collaborative Research

PeDRA’s mission is to promote and facilitate high quality collaborative clinical, translational, educational and basic science research in pediatric dermatology. Along with this mission is the vision to create sustainable collaborative research networks to better understand, prevent, treat and cure dermatological diseases in children.

http://pedraresearch.org
Follow us: Facebook: PeDRAresearch  Twitter: @PeDRAresearch

Questions? Please contact:
Sheila Rittenberg, PeDRA Executive Director, sheila.pedraresearch@gmail.com
Jennifer Dawson, Membership & Outreach Liaison, jenn.pedraresearch@gmail.com

<< BACK